This article highlights a new study showing that Nirmatrelvil, the active ingredient in Paxlovid, prevents an adequate adaptive immune response to the SARS-CoV-2 virus. In the study, the SARS-CoV-2-infected mice failed to develop antibodies, memory T cells, and B cells specific to SARS-CoV-2 on initial and second exposure to the virus. The K18-hACE2 mice used…
Paxlovid blunts adaptive immune response to SARS-CoV-2
Posted on